Risperdal® and Breast Cancer Risk

Risperdal® (risperidone) is an antipsychotic medication manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It has been widely prescribed to treat conditions such as schizophrenia, bipolar disorder, and irritability associated with autism. While effective for many patients, Risperdal® has long been associated with a serious side effect: elevated levels of the hormone prolactin, a condition known as hyperprolactinemia.

Hyperprolactinemia can cause a range of complications, including abnormal breast growth, milk production, and hormonal disruption. Alarmingly, research has now suggested that prolonged elevated prolactin levels may increase the risk of developing breast cancer. Women who have taken Risperdal® may face heightened concerns about this potential link and its impact on their long-term health.

Parafinczuk Wolf is actively investigating claims on behalf of individuals who developed breast cancer potentially related to Risperdal® use. If you or a loved one has been diagnosed with breast cancer after taking Risperdal®, we encourage you to reach out to us. Our team has extensive experience in complex pharmaceutical litigation, and we are committed to holding manufacturers accountable for the safety of their products.

Please contact Parafinczuk Wolf at 954-462-6700 today for a free consultation.